The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Open accessAbstract
IMPORTANCE: The programmed death 1 (PD-1) pathway limits immune responses to melanoma and can be blocked with the humanized anti-PD-1 monoclonal antibody pembrolizumab. OBJECTIVE: To characterize the association of pembrolizumab with tumor response and overall survival among patients with advanced melanoma. DESIGN, SETTINGS, AND PARTICIPANTS: Open-label, multicohort, phase 1b clinical trials (enrollment, December 2011-September 2013). Median duration of follow-up was 21 months. The study was performed in academic medical centers in Australia, Canada, France, and the United States. Eligible patients were aged 18 years and older and had advanced or metastatic melanoma. Data were pooled from 655 enrolled patients (135 from a nonrandomized cohort [n = 87 ipilimumab naive; n = 48 ipilimumab treated] and 520 from randomized cohorts [n = 226 ipilimumab naive; n = 294 ipilimumab treated]). Cutoff dates were April 18, 2014, for safety analyses and October 18, 2014, for efficacy analyses. EXPOSURES: Pembrolizumab 10 mg/kg every 2 weeks, 10 mg/kg every 3 weeks, or 2 mg/kg every 3 weeks continued until disease progression, intolerable toxicity, or investigator decision. MAIN OUTCOMES AND MEASURES: The primary end point was confirmed objective response rate (best overall response of complete response or partial response) in patients with measurable disease at baseline per independent central review. Secondary end points included toxicity, duration of response, progression-free survival, and overall survival. RESULTS: Among the 655 patients (median [range] age, 61 [18-94] years; 405 [62%] men), 581 had measurable disease at baseline. An objective response was reported in 194 of 581 patients (33% [95% CI, 30%-37%]) and in 60 of 133 treatment-naive patients (45% [95% CI, 36% to 54%]). Overall, 74% (152/205) of responses were ongoing at the time of data cutoff; 44% (90/205) of patients had response duration for at least 1 year and 79% (162/205) had response duration for at least 6 months. Twelve-month progression-free survival rates were 35% (95% CI, 31%-39%) in the total population and 52% (95% CI, 43%-60%) among treatment-naive patients. Median overall survival in the total population was 23 months (95% CI, 20-29) with a 12-month survival rate of 66% (95% CI, 62%-69%) and a 24-month survival rate of 49% (95% CI, 44%-53%). In treatment-naive patients, median overall survival was 31 months (95% CI, 24 to not reached) with a 12-month survival rate of 73% (95% CI, 65%-79%) and a 24-month survival rate of 60% (95% CI, 51%-68%). Ninety-two of 655 patients (14%) experienced at least 1 treatment-related grade 3 or 4 adverse event (AE) and 27 of 655 (4%) patients discontinued treatment because of a treatment-related AE. Treatment-related serious AEs were reported in 59 patients (9%). There were no drug-related deaths. CONCLUSIONS AND RELEVANCE: Among patients with advanced melanoma, pembrolizumab administration was associated with an overall objective response rate of 33%, 12-month progression-free survival rate of 35%, and median overall survival of 23 months; grade 3 or 4 treatment-related AEs occurred in 14%. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01295827.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Immune checkpoint blockade with monoclonal antibodies (mAbs) targeting programmed cell death protein 1 (PD-1) provides long-term clinical benefits to nearly 40% of patients with advanced melanoma (1–5).”
From Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients (2021) · cites this paper as [2]
In the citing paper
“Both CTLA-4 and PD-1 act independently as brakes on CD3/CD28-dependent signaling, suggesting that underlying immune responses are required for checkpoint inhibitor treatment to take effect (66).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [66]
In the citing paper
“In melanoma, anti-PD-1 treatment was more effective in patients with smaller tumors (66).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [66]
In the citing paper
“Both CTLA-4 and PD-1 act independently as brakes on CD3/CD28-dependent signaling, suggesting that underlying immune responses are required for checkpoint inhibitor treatment to take effect (66).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [66]
In the citing paper
“For example, patients with smaller tumors or low serum lactate dehydrogenase (LDH) levels at baseline have a better prognosis and are also more likely to respond to anti-PD-1 treatment (66).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [66]
In the citing paper
“Patients more likely to benefit from checkpoint immunotherapy include those with tumors demonstrating a high density of somatic mutations, elevated PD-L1 expression and/or are enriched with IFNγ transcriptional profiles (8–13).”
From Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis (2019) · cites this paper as [11]
In the citing paper
“The degree of tumor inflammation, as assessed by the presence of type I/II IFN signaling and infiltrating effector T cells, is associated with an improved response to checkpoint immunotherapy (8–11,13).”
From Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis (2019) · cites this paper as [11]
In the citing paper
“Anti-PD-1 immunotherapy has shown efficacy in melanoma, but fewer than half of all melanoma patients treated with anti-PD-1 immunotherapy have a prolonged response5.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationTHE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Clopper, C. J., & Pearson, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,327
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 4,057
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,427
Self-citationWolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214
Self-citationTopalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Self-citation
Flagged first, then by citations
Research works printed but not linked: 4
- Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma. Lancet. 2014;384(9948):1109-1117.
- Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002). Lancet Oncol. 2015;16(8):908-918.
- Joseph RW, Elassaiss-Schaap J, Wolchok JD, et al. Baseline tumor size (BTS) and PD-L1 expression are independently associated with clinical outcomes in patients (pts) with metastatic melanoma (MM) treated with pembrolizumab (pembro; MK-3475). Abstract presented at: Society for Melanoma Research 2014 Congress; November 13-16, 2014; Zurich, Switzerland. Pigment Cell Melanoma Res. 2014;27:1188.
- Kluger HM, Sznol M, Callahan MK et al. Survival, response duration and activity by BRAF mutation status in a phase 1 trial of nivolumab (anti-PD-1; BMS-936558,ONO-4538) and ipilimumab concurrent therapy in advanced melanoma (MEL). Abstract presented at: Society for Melanoma Research 2014 Congress; November 13-16, 2014; Zurich, Switzerland. Pigment Cell Melanoma Res. 2014;27:1203.
Cited by
Sorted by citations
Items 101–200 of 1,000
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Diggs, L. P., & Hsueh, E. C. (2017) · Biomarker Research · doi:10.1186/s40364-017-0093-8 · Cited by 179
Exosomal PD-L1: Roles in Tumor Progression and Immunotherapy
Morrissey, S. M., & Yan, J. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.03.002 · Cited by 174
Yan, Y., Cao, S., Liu, X., Harrington, S. M., Bindeman, W. E., Adjei, A. A., Jang, J. S., Jen, J., Li, Y., Chanana, P., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.97828 · Cited by 170
Self-citationMeder, L., Schuldt, P., Thelen, M., Schmitt, A., Dietlein, F., Klein, S., Borchmann, S., Wennhold, K., Vlašić, I., Oberbeck, S., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2176 · Cited by 176
Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies
Dubey, D., David, W. S., Amato, A. A., Reynolds, K. L., Clement, N. F., Chute, D. F., Cohen, J. V., Lawrence, D. P., Mooradian, M. J., Sullivan, R. J., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008091 · Cited by 171
Self-citationDaneshmandi, S., Wegiel, B., & Seth, P. (2019) · Cancers · doi:10.3390/cancers11040450 · Cited by 170
IFNγ-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin
Lane, R. S., Femel, J., Breazeale, A. P., Loo, C. P., Thibault, G., Kaempf, A. J., Mori, M., Tsujikawa, T., Chang, Y. H., & Lund, A. W. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20180654 · Cited by 168
Cristescu, R., Aurora-Garg, D., Albright, A. V., Xu, L., Liu, X. Q., Loboda, A. P., Lang, L., Jin, F., Rubin, E. H., Snyder, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003091 · Cited by 172
Abdel-Rahman, O. M., Oweira, H., Petrausch, U., Helbling, D., Schmidt, J., Mannhart, M., Mehrabi, A., Schöb, O. M., & Giryes, A. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1296765 · Cited by 163
Intratumoral Immunotherapy—Update 2019
Hamid, O., Ismail, R., & Puzanov, I. J. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0438 · Cited by 161
Self-citationApplications of single-cell and bulk RNA sequencing in onco-immunology
Kuksin, M., Morel, D., Aglave, M., Danlos, F., Marabelle, A., Zinovyev, A. Y., Gautheret, D., & Verlingue, L. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.005 · Cited by 172
Synthetic lethality-mediated precision oncology via the tumor transcriptome
Lee, J. S., Nair, N. U., Dinstag, G., Chapman, L. M., Chung, Y., Wang, K., Sinha, S., Cha, H., Kim, D., Schperberg, A. V., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.030 · Cited by 158
Cardiovascular Toxicities Associated with Cancer Immunotherapies
Wang, D. Y., Okoye, G. D., Neilan, T., Johnson, D. B., & Moslehi, J. J. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0835-0 · Cited by 161
Zhou, C., Wei, W.-F., Ma, J., Yang, Y., Liang, L.-J., Zhang, Y., Wang, Z., Chen, X., Huang, L., Wang, W., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.034 · Cited by 157
Nair, V. S., Salhat, H. E., Taha, R. Z., John, A., Ali, B. R., & Elkord, E. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0512-1 · Cited by 157
Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity
Mender, I., Zhang, A., Ren, Z., Han, C., Deng, Y., Siteni, S., Li, H., Zhu, J., Vemula, A., Shay, J. W., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.05.020 · Cited by 149
Natale, C. A., Li, J., Zhang, J., Dahal, A., Dentchev, T., Stanger, B. Z., & Ridky, T. W. (2018) · eLife · doi:10.7554/elife.31770 · Cited by 155
Tan, Y. S., Sansanaphongpricha, K., Xie, Y., Donnelly, C. R., Luo, X., Heath, B. R., Zhao, X., Bellile, E. L., Hu, H., Chen, H., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2807 · Cited by 155
The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma
Lim, S. Y., Shklovskaya, E., Lee, J., Pedersen, B., Stewart, A., Ming, Z., Irvine, M., Shivalingam, B., Saw, R. P. M., Menzies, A. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36979-y · Cited by 161
Bullock, A. J., Schlechter, B. L., Fakih, M., Tsimberidou, A. M., Grossman, J. E., Gordon, M. S., Wilky, B. A., Pimentel, A., Mahadevan, D., Balmanoukian, A. S., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03083-7 · Cited by 160
Vasconcelos, M. H., Caires, H. R., Ābols, A., Xavier, C. P. R., & Linē, A. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100647 · Cited by 150
Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy
Falcone, I., Conciatori, F., Bazzichetto, C., Ferretti, G., Cognetti, F., Ciuffreda, L., & Milella, M. (2020) · Cancers · doi:10.3390/cancers12102870 · Cited by 151
Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion
Freeman, A. J., Vervoort, S. J., Ramsbottom, K. M., Kelly, M. J., Michie, J., Pijpers, L., Johnstone, R. W., Kearney, C. J., & Oliaro, J. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.017 · Cited by 140
Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers
Majzner, R. G., Heitzeneder, S., & Mackall, C. L. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.03.002 · Cited by 144
Zager, J. S., Gastman, B., Leachman, S. A., Gonzalez, R. C., Fleming, M. D., Ferris, L. K., Ho, J., Miller, A. R., Cook, R. W., Covington, K. R., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4016-3 · Cited by 141
Kim, W., Chu, T. H., Nienhüser, H., Jiang, Z., Portillo, A. D., Remotti, H. E., White, R. A., Hayakawa, Y., Tomita, H., Fox, J. G., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.10.036 · Cited by 141
Zhang, Y., Chen, H., Mo, H., Zhao, N., Sun, X., Liu, B., Gao, R., Xu, B., Zhang, Z., Liu, Z., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.01.007 · Cited by 153
Direct and indirect regulation of the tumor immune microenvironment by VEGF
Zhang, Y., & Brekken, R. A. (2022) · Journal of Leukocyte Biology · doi:10.1002/jlb.5ru0222-082r · Cited by 141
Si, L., Zhang, X., Shu, Y., Pan, H., Wu, D., Liu, J., Lou, F., Mao, L., Wang, X., Wen, X., et al. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.02.007 · Cited by 133
Beyond T Cells: Understanding the Role of PD-1/PD-L1 in Tumor-Associated Macrophages
Lu, D., Ni, Z., Liu, X., Feng, S., Dong, X., Shi, X., Zhai, J., Mai, S., Jiang, J., Wang, Z., et al. (2019) · Journal of Immunology Research · doi:10.1155/2019/1919082 · Cited by 134
Seban, R., Nemer, J. S., Marabelle, A., Yeh, R., Deutsch, É., Ammari, S., Moya‐Plana, A., Mokrane, F., Gartrell, R. D., Finkel, G. G., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04411-7 · Cited by 136
Self-citationCell Softness Prevents Cytolytic T Cell Killing of Tumor-Repopulating Cells
Liu, Y., Zhang, T., Zhou, N., Fiskesund, R., Liang, X., Chen, J., Lv, J., Xie, J., Ma, J., Zhang, H., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-20-2569 · Cited by 134
Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy
Wang, Y., Liu, S., Yang, Z., Algazi, A. P., Lomeli, S. H., Wang, Y., Othus, M. K. D., Hong, A., Wang, X., Randolph, C. E., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.023 · Cited by 135
Self-citationSpatial transcriptomics and proteomics technologies for deconvoluting the tumor microenvironment
Wang, N., Li, X., Wang, R., & Ding, Z. (2021) · Biotechnology Journal · doi:10.1002/biot.202100041 · Cited by 136
Self-citationLi, J., Ren, H., Qiu, Q., Yang, X., Zhang, J., Zhang, C., Sun, B., Lovell, J. F., & Zhang, Y. (2022) · ACS Nano · doi:10.1021/acsnano.2c06926 · Cited by 131
Mechanisms of Resistance to Immune Checkpoint Blockade
Liu, D., Jenkins, R. W., & Sullivan, R. J. (2018) · American Journal of Clinical Dermatology · doi:10.1007/s40257-018-0389-y · Cited by 135
Toll-Like Receptor 9 Agonists in Cancer
Karapetyan, L., Luke, J. J., & Davar, D. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s247050 · Cited by 138
Nosrati, A., Tsai, K. K., Goldinger, S. M., Tumeh, P. C., Grimes, B. A., Loo, K. L., Algazi, A. P., Nguyen‐Kim, T. D. L., Levesque, M. P., Dummer, R., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.70 · Cited by 126
Self-citationPD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade
Hirsch, L., Zitvogel, L., Eggermont, A. M. M., & Marabelle, A. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0294-4 · Cited by 131
Wagner, N. B., Forschner, A., Leiter, U., Garbe, C., & Eigentler, T. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0167-x · Cited by 129
Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade
Ariyan, C. E., Brady, M. S., Siegelbaum, R. H., Hu, J., Bello, D. M., Rand, J. G., Fisher, C., Lefkowitz, R. A., Panageas, K. S., Pulitzer, M. P., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0356 · Cited by 126
Self-citationCombatting Mucosal Melanoma: Recent Advances and Future Perspectives
Tyrrell, H. E. J., & Payne, M. (2018) · Melanoma Management · doi:10.2217/mmt-2018-0003 · Cited by 123
Queirolo, P., & Spagnolo, F. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.07.002 · Cited by 121
Zhu, B., Tang, L., Chen, S., Yin, C., Peng, S., Li, X., Liu, T., Liu, W., Han, C., Stawski, L., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0314-0 · Cited by 117
Self-citationBasal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond
Bakshi, A., Chaudhary, S. C., Rana, M., Elmets, C. A., & Athar, M. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22690 · Cited by 122
Signal pathways and precision therapy of small-cell lung cancer
Yuan, M., Zhao, Y., Arkenau, H., Lao, T., Chu, L., & Xu, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01013-y · Cited by 117
Predictors of Immunotherapy-Induced Immune-Related Adverse Events
Kartolo, A., Sattar, J., Sahai, V., Baetz, T. D., & Lakoff, J. M. (2018) · Current Oncology · doi:10.3747/co.25.4047 · Cited by 119
Sun, Z., Wang, Z., Wang, T., Wang, J., Zhang, H., Li, Z., Wang, S., Sheng, F., Yu, J. X., & Hou, Y. (2022) · ACS Nano · doi:10.1021/acsnano.2c00969 · Cited by 120
Long, J., Lin, J., Wang, A., Wu, L., Zheng, Y., Yang, X., Wan, X., Xu, H., Chen, S., & Zhao, H. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0511-2 · Cited by 115
Bai, X., Fisher, D. E., & Flaherty, K. T. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0204-6 · Cited by 107
Nishino, M., Ramaiya, N. H., Chambers, E. S., Adeni, A. E., Hatabu, H., Janne, P. A., Hodi, F. S., & Awad, M. M. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0193-2 · Cited by 117
Self-citationO’Connor, J. M., Fessele, K. L., Steiner, J., Seidl-Rathkopf, K., Carson, K. R., Nussbaum, N. C., Yin, E. S., Adelson, K. B., Presley, C. J., Chiang, A. C., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0798 · Cited by 114
Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy
Ahern, E. S., Smyth, M. J., Dougall, W. C., & Teng, M. W. L. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0095-y · Cited by 115
Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
Jiang, Y., Zhao, X., Fu, J., & Wang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00339 · Cited by 115
Ugurel, S., Röhmel, J., Ascierto, P. A., Becker, J. C., Flaherty, K. T., Grob, J., Hauschild, A., Larkin, J., Livingstone, E., Long, G. V., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.02.021 · Cited by 114
Self-citationPD-L1 testing by immunohistochemistry in immuno-oncology
Vranić, S., & Gatalica, Z. (2022) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2022.7953 · Cited by 120
Kang, S., Gergich, K., Lubiniecki, G. M., de Alwis, D. P., Chen, C., Tice, M. A. B., & Rubin, E. H. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx076 · Cited by 113
Self-citationThe local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy
Yuan, W., Zhao, Q., Gao, Z., Lao, X., Lin, W., Chen, D., Mu, M., Huang, C.-X., Liu, Z., Li, B., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127726 · Cited by 114
Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity
Mittica, G., Ghisoni, E., Giannone, G., Aglietta, M., Genta, S., & Valabrega, G. (2017) · Oncotarget · doi:10.18632/oncotarget.20042 · Cited by 113
Zhao, Z., Ding, Y., Tran, L. J., Chai, G., & Li, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1196892 · Cited by 111
Checkpoint Inhibitor–Induced Colitis
Bellaguarda, E., & Hanauer, S. B. (2020) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000497 · Cited by 107
Cutaneous melanoma and the immunotherapy revolution (Review)
Leonardi, G. C., Candido, S., Falzone, L., Spandidos, D. A., & Libra, M. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5088 · Cited by 107
Lan, X., Zhu, W., Huang, X., Yu, Y., Xiao, H., Jin, L., Pu, J. J., Xie, X., She, J., Lui, V. W. Y., et al. (2020) · Nanoscale · doi:10.1039/d0nr04213g · Cited by 107
Boyero, L., Sánchez-Gastaldo, A., Alonso, M. D., Noguera-Uclés, J. F., Molina‐Pinelo, S., & Bernabé, R. (2020) · Cancers · doi:10.3390/cancers12123729 · Cited by 107
Robert, C., Hwu, W., Hamid, O., Ribas, A., Weber, J. S., DAUD, A. I., Hodi, F. S., Wolchok, J. D., Mitchell, T. C., Hersey, P., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.11.010 · Cited by 104
Self-citationSoluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
Morello, S., Capone, M., Sorrentino, C., Giannarelli, D., Madonna, G., Mallardo, D., Grimaldi, A. M., Pinto, A., & Ascierto, P. A. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1348-8 · Cited by 103
Nakajima, Y., Chamoto, K., Oura, T., & Honjo, T. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103730118 · Cited by 103
Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
Parakh, S., Park, J., Mendis, S. R., Rai, R., Xu, W., Lo, S., Drummond, M., Rowe, C. E., Wong, A. N. M., McArthur, G. A., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.142 · Cited by 105
Self-citationAdoptive T cell therapy: An overview of obstacles and opportunities
Baruch, E. N., Berg, A. L., Besser, M. J., Schachter, J., & Markel, G. (2017) · Cancer · doi:10.1002/cncr.30491 · Cited by 104
Talimogene Laherparepvec: Review of its Mechanism of Action and Clinical Efficacy and Safety
Raman, S. S., Hecht, J. R., & Chan, E. (2019) · Immunotherapy · doi:10.2217/imt-2019-0033 · Cited by 102
Moy, J. D., Moskovitz, J. M., & Ferris, R. L. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.035 · Cited by 102
Carlino, M. S., Long, G. V., Schadendorf, D., Robert, C., Ribas, A., Richtig, E., Nyakas, M., Caglevic, C., Tarhini, A., Blank, C. U., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.06.034 · Cited by 101
Self-citationKuryk, Ł., Møller, A. W., & Jaderberg, M. E. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1532763 · Cited by 100
Ultraviolet Radiation and Melanomagenesis: From Mechanism to Immunotherapy
Sun, X., Zhang, N., Yin, C., Zhu, B., & Li, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00951 · Cited by 106
Self-citationEpigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors
Perrier, A., Didelot, A., Laurent‐Puig, P., Blons, H., & Garinet, S. (2020) · Biomolecules · doi:10.3390/biom10071061 · Cited by 100
Exosomal PD‐L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies
Zhou, K., Guo, S., Li, F., Sun, Q., & Liang, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.569219 · Cited by 99
Tamiya, M., Tamiya, A., Inoue, T., Kimura, M., Kunimasa, K., Nakahama, K., Taniguchi, Y., Shiroyama, T., Isa, S., Nishino, K., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192227 · Cited by 98
Liquid biomarkers in melanoma: detection and discovery
Lim, S. Y., Lee, J., Diefenbach, R. J., Kefford, R. F., & Rizos, H. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0757-5 · Cited by 99
Self-citationYu, D., Zhang, S., Feng, A., Xu, D., Zhu, Q., Mao, Y., Zhao, Y., Lv, Y., Han, C., Liu, R., et al. (2019) · Medicine · doi:10.1097/md.0000000000015582 · Cited by 99
Gastman, B., Gerami, P., Kurley, S. J., Cook, R. W., Leachman, S. A., & Vetto, J. T. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.07.028 · Cited by 97
Fang, T., Alvelid, J., Spratt, J., Ambrosetti, E., Testa, I., & Teixeira, A. I. (2021) · ACS Nano · doi:10.1021/acsnano.0c10632 · Cited by 91
Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy
Krishnamoorthy, M., Gerhardt, L., & Vareki, S. M. (2021) · Cells · doi:10.3390/cells10051170 · Cited by 100
Marked Global DNA Hypomethylation Is Associated with Constitutive PD-L1 Expression in Melanoma
Chatterjee, A., Rodger, E. J., Ahn, A., Stockwell, P. A., Parry, M. F., Motwani, J., Gallagher, S. J., Shklovskaya, E., Tiffen, J. C., Eccles, M. R., et al. (2018) · iScience · doi:10.1016/j.isci.2018.05.021 · Cited by 92
Self-citationTargeting the ubiquitination/deubiquitination process to regulate immune checkpoint pathways
Liu, J., Cheng, Y., Zheng, M., Yuan, B., Wang, Z., Li, X., Yin, J., Ye, M., & Song, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00418-x · Cited by 94
Self-citationEstimated Healthcare Costs of Melanoma in Australia Over 3 Years Post-Diagnosis
Elliott, T. M., Whiteman, D. C., Olsen, C. M., & Gordon, L. G. (2017) · Applied Health Economics and Health Policy · doi:10.1007/s40258-017-0341-y · Cited by 92
Mari, L., Hoefnagel, S. J. M., Zito, D., van de Meent, M., Endert, P. V., Calpe, S., Sancho‐Serra, M. D. C., Heemskerk, M. H. M., van Laarhoven, H. W. M., Hulshof, M. C. C. M., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.06.030 · Cited by 91
Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma
Abu‐Sbeih, H., Ali, F. S., Qiao, W., Lü, Y., Patel, S. P., Diab, A. K., & Wang, Y. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02303-1 · Cited by 88
The Resistance Mechanisms of Lung Cancer Immunotherapy
Wang, F., Wang, S., & Zhou, Q. H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.568059 · Cited by 90
Cancer in Inflammatory Bowel Disease
Faye, A. S., Holmer, A. K., & Axelrad, J. E. (2022) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2022.05.003 · Cited by 87
Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma
Davar, D., Wang, H., Chauvin, J.-M., Pagliano, O., Fourcade, J. J., Ka, M., Menna, C., Rose, A., Sander, C., Borhani, A. A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00632 · Cited by 86
Self-citationGlitza, I. C., Seo, Y. D., Spencer, C. N., Wortman, J. R., Burton, E. M., Alayli, F. A., Loo, C. P., Gautam, S., Damania, A., Densmore, J., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0066 · Cited by 87
Self-citationChang, X., Lu, X., Guo, J., & Teng, G. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.08.006 · Cited by 86
Shen, N., Wu, J., Yang, C., Yu, H., Yang, S., Li, T., Chen, J., Tang, Z., & Chen, X. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b03214 · Cited by 85
Uveitis in Patients Treated with CTLA-4 and PD-1 Checkpoint Blockade Inhibition
Sun, M. M., Levinson, R. D., Filipowicz, A., Anesi, S. D., Kaplan, H. J., Wang, W., Goldstein, D. A., Gangaputra, S. S., Swan, R. T., Sen, H. N., et al. (2019) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2019.1577978 · Cited by 85
Guo, L., Wei, R., Lin, Y., & Kwok, H. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01508 · Cited by 85
Ballerini, M., Galié, S., Tyagi, P., Catozzi, C., Raji, H., Nabinejad, A., Macandog, A. D. G., Cordiale, A., Slivinschi, B. I., Kugiejko, K. K., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01318-z · Cited by 98
Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy
Loo, K. L., Tsai, K. K., Mahuron, K. M., Liu, J., Pauli, M. L., Sandoval, P. M., Nosrati, A., Lee, J., Chen, L., Hwang, J. J., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93433 · Cited by 84
Self-citationMetastatic Extramammary Paget’s Disease: Pathogenesis and Novel Therapeutic Approach
Fukuda, K., & Funakoshi, T. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00038 · Cited by 87
Sensitive Detection and Analysis of Neoantigen-Specific T Cell Populations from Tumors and Blood
Peng, S., Zaretsky, J. M., Ng, A. H. C., Chour, W., Bethune, M. T., Choi, J., Hsu, A. C., Holman, E. A., Ding, X., Guo, K. L., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.106 · Cited by 84
Self-citationLiu, J.-R., Yu, C., Hung, P.-Y., Hsin, L., & Chern, J. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.03.023 · Cited by 84
Metadata
- Authors
- Ribas, A., Hamid, O., Daud, A., Hodi, F. S., Wolchok, J. D., Kefford, R., Joshua, A. M., Patnaik, A., Hwu, W.-J., Weber, J. S., Gangadhar, T. C., Hersey, P., Dronca, R., Joseph, R. W., Zarour, H., Chmielowski, B., Lawrence, D. P., Algazi, A., Rizvi, N. A., Hoffner, B., Mateus, C., Gergich, K., Lindia, J. A., Giannotti, M., Li, X. N., Ebbinghaus, S., Kang, S. P., & Robert, C.
- Affiliations
- University of California, Los Angeles (US)
- Angeles Clinic and Research Institute (US)
- University of California, San Francisco (US)
- Dana-Farber Cancer Institute (US)
- Memorial Sloan Kettering Cancer Center (US)
- Westmead Hospital (AU)
- Princess Margaret Cancer Centre (CA)
- South Texas Accelerated Research Therapeutics (US)
- The University of Texas MD Anderson Cancer Center (US)
- Moffitt Cancer Center (US)
- Abramson Cancer Center (US)
- The University of Sydney (AU)
- Mayo Clinic (US)
- Mayo Clinic in Florida (US)
- University of Pittsburgh (US)
- Massachusetts General Hospital (US)
- Institut Gustave Roussy (FR)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Ribas, Antoni
- ORCID
- Ribas, Antoni
- Hamid, Omid
- Daud, Adil
- Hodi, F. Stephen
- Wolchok, Jedd D.
- Kefford, Richard
- Joshua, Anthony M.
- Patnaik, Amita
- Hwu, Wen-Jen
- Weber, Jeffrey S.
- Hersey, Peter
- Dronca, Roxana
- Joseph, Richard W.
- Zarour, Hassane
- Chmielowski, Bartosz
- Lawrence, Donald P.
- Algazi, Alain
- Rizvi, Naiyer A.
- Mateus, Christine
- Li, Xiaoyun Nicole
- Robert, Caroline
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2016-04-19
- Volume
- 315
- Issue
- 15
- Pages
- 1600
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2338494814
- Cited by
- 1,069
- References
- 22
- Citations by year
- 2026: 33 · 2025: 66 · 2024: 67 · 2023: 99 · 2022: 63 · 2021: 123 · 2020: 139 · 2019: 139 · 2018: 145 · 2017: 153 · 2016: 39
- FWCI
- 85.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- pembrolizumab, advanced melanoma, metastatic melanoma, anti-PD-1 therapy, anti-PD-1 monoclonal antibody, objective response rate, overall survival, progression-free survival, duration of response, ipilimumab, immune checkpoint inhibitors, treatment-naive patients, treatment-emergent adverse events, immune-related adverse events, immune-related pneumonitis, immune-related colitis
- MeSH terms
- Ipilimumab, Adult, Aged, Aged, 80 and over, Algorithms, Antibodies, Monoclonal, Antineoplastic Agents, Drug Administration Schedule, Female, Humans, Male, Melanoma, Middle Aged, Skin Neoplasms, Survival Rate, Treatment Outcome, Disease Progression, Disease-Free Survival, Young Adult, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
